Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Daniel J
DJ
Lenihan
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D009536:Niacinamide / Q000031:analogs & derivatives; D010348:Patient Care Team; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D012307:Risk Factors; D000077157:Sorafenib; D000077210:Sunitinib; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib